Last reviewed · How we verify
Pegmolesatide
At a glance
| Generic name | Pegmolesatide |
|---|---|
| Also known as | EPO-018B |
| Sponsor | The First Affiliated Hospital of Dalian Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) (NA)
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis (PHASE4)
- Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegmolesatide CI brief — competitive landscape report
- Pegmolesatide updates RSS · CI watch RSS
- The First Affiliated Hospital of Dalian Medical University portfolio CI